Search Results - "CHONG, Geoff"

Programmed cell death-1 inhibition in lymphoma by Hawkes, Eliza A, Dr, Grigg, Andrew, Prof, Chong, Geoff, MD

“…Summary Cancers can evade the host immune system by inducing upregulation of immune inhibitory signals. Anti-programmed cell death-1 (PD-1) monoclonal…”
Get full text

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance by Barraclough, Allison, England, James T, Villa, Diego, Wight, Joel, Hapgood, Greg, Conn, Jason, Doo, Nicole Wong, Li, Eric Wenlong, Gilbertson, Michael, Shaw, Briony, Bishton, Mark J, Saeed, Malik, Ratnasingam, Sumita, Abeyakoon, Chathuri, Chong, Geoff, Wai, Shin Hnin, Ku, Matthew, Lee, Hui-Peng, Fleming, Kathryn, Tam, Constantine, Douglas, Genevieve, Cheah, Chan Y, Ng, Zi Yun, Rolfe, Tukten, Mills, Anthony K, Hamad, Nada, Cashman, Helen, Gleeson, Mary, Narayana, Manjunath, Hawkes, Eliza A

“…Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between 'low-grade' (Grade 1, 2 and 3A FL) and diffuse…”
Get full text

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14 by Hertzberg, Mark, Gandhi, Maher K, Trotman, Judith, Butcher, Belinda, Taper, John, Johnston, Amanda, Gill, Devinder, Ho, Shir-Jing, Cull, Gavin, Fay, Keith, Chong, Geoff, Grigg, Andrew, Lewis, Ian D, Milliken, Sam, Renwick, William, Hahn, Uwe, Filshie, Robin, Kannourakis, George, Watson, Anne-Marie, Warburton, Pauline, Wirth, Andrew, Seymour, John F, Hofman, Michael S, Hicks, Rodney J

“…In the treatment of diffuse large B-cell lymphoma, a persistently positive [ F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a…”
Get full text

Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer by WEICKHARDT, Andrew J, PRICE, Tim J, SALEMI, Renato, SCOTT, Andrew M, MARIADASON, John M, TEBBUTT, Niall C, CHONG, Geoff, GEBSKI, Val, PAVLAKIS, Nick, JOHNS, Terrance G, AZAD, Arun, SKRINOS, Effie, FLUCK, Kate, DOBROVIC, Alexander

“…This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC). The…”
Get full text

Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation by RISCHIN, Danny, BIBBY, David C, CHONG, Geoff, KREMMIDIOTIS, Gabriel, LESKE, Annabell F, MATTHEWS, ClaytonA, WONG, ShirleyS, ROSEN, Mark A, DESAI, Jayesh

“…To determine the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and pharmacodynamic (PD) effects of BNC105P,…”
Get full text

P1230: T CELL CD62L EXPRESSION FOLLOWING NIVOLUMAB THERAPY IS ASSOCIATED WITH LONG TERM RESPONSE TO RITUXIMAB‐NIVOLUMAB IN TREATMENT NAÏVE FOLLICULAR LYMPHOMA: RESULTS FROM THE 1ST FLOR STUDY by Koldej, Rachel, Barraclough, Allison, Ting Lee, Sze, Morgan, Huw, Holzwart, Nicholas, Koshy, Minu, Smith, Charmaine, Chong, Geoff, Gilbertson, Michael, Keane, Colm, Ting, Stephen, Churilov, Leonid, Ritchie, David, Hawkes, Eliza A.

Get full text

P1193: POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA‐BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL‐INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY by Shaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoff, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen, Hawkes, Eliza A

Get full text

Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience by Arkenau, Hendrik-Tobias, Chong, Geoff, Cunningham, David, Watkins, David, Sirohi, Bhawna, Chau, Ian, Wotherspoon, Andrew, Norman, Andy, Horwich, Alan, Matutes, Estella

“…* Department of Medicine, Royal Marsden Hospital, London and Sutton ° Department of Histopathology, Royal Marsden Hospital, London # Department of Computing,…”
Get full text

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study by Dasari, Arvind, Lonardi, Sara, Garcia-Carbonero, Rocio, Elez, Elena, Yoshino, Takayuki, Sobrero, Alberto, Yao, James, García-Alfonso, Pilar, Kocsis, Judit, Cubillo Gracian, Antonio, Sartore-Bianchi, Andrea, Satoh, Taroh, Randrian, Violaine, Tomasek, Jiri, Chong, Geoff, Paulson, Andrew Scott, Masuishi, Toshiki, Jones, Jeremy, Csőszi, Tibor, Cremolini, Chiara, Ghiringhelli, Francois, Shergill, Ardaman, Hochster, Howard S, Krauss, John, Bassam, Ali, Ducreux, Michel, Elme, Anneli, Faugeras, Laurence, Kasper, Stefan, Van Cutsem, Eric, Arnold, Dirk, Nanda, Shivani, Yang, Zhao, Schelman, William R, Kania, Marek, Tabernero, Josep, Eng, Cathy

“…There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the…”
Get full text

Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study by Chong, Geoff, Palmer, Jodie B, Barraclough, Allison A, Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine, Hawkes, Eliza A

“…Background: Follicular lymphoma (FL) outcomes are influenced by tumour microenvironment composition and manipulation. As patients (pts) with FL are…”
Get full text

Frontline treatment of follicular lymphoma with atezolizumab and obinutuzumab, with and without radiotherapy (The FLUORO study) by Hawkes, Eliza Anne, Manos, Kate, Khor, Richard, Douglas, Genevieve, Lee, Sze Ting, Lee, Denise, Campbell, Belinda, Grobler, Anneke, Gilbertson, Michael, Palmer, Jodie, Chong, Geoff

“…TPS7587 Background: Follicular lymphoma (FL) is the commonest indolent lymphoma, comprising 20% of non-Hodgkin Lymphoma, with approximately 80% of patients…”
Get full text

Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab by Ku, Matthew, Chong, Geoff, Hawkes, Eliza A

“…Abstract Recent proliferation of novel targeted therapies in lymphoma has been substantial. B-cell receptor pathway inhibitors and immune checkpoint inhibitors…”
Get full text

Addressing disparities in health outcomes for patients with advanced pancreatic cancer and limited English proficiency by Williams, Colin, Chong, Geoff, Tacey, Mark, Barnett, Frances, Mooi, Jennifer, Jalali, Azim, Hodgson, Russell, Yong, Tuck, Lee, Belinda

“…Introduction There are significant challenges and a lack of data related to culturally and linguistically diverse (CALD) cancer patients. We compared patient…”
Get full text

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study by TEBBUTT, Niall C, WILSON, Kate, FORGESON, Garry, CUNNINGHAM, David, SAUNDERS, Mark P, STOCKLER, Martin R, CHUA, Yujo, ZALCBERG, John R, SIMES, R. John, PRICE, Timothy J, GEBSKI, Val J, CUMMINS, Michelle M, ZANNINO, Diana, VAN HAZEL, Guy A, ROBINSON, Bridget, BROAD, Adam, GANJU, Vinod, ACKLAND, Stephen P

“…To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with…”
Get full text

Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study by Eng, Cathy, Dasari, Arvind, Lonardi, Sara, Garcia-Carbonero, Rocio, Elez, Elena, Yoshino, Takayuki, Sobrero, Alberto F., Yao, James C., Garcia-Alfonso, Pilar, Kocsis, Judit, Cubillo, Antonio, Sartore-Bianchi, Andrea, Satoh, Taroh, Randrian, Violaine, Tomasek, Jiri, Chong, Geoff, Yang, Zhao, Guevara, Ferdinand M., Schelman, William R., Tabernero, Josep

“…3601 Background: Fruquintinib (F) is a highly selective and potent inhibitor of VEGFRs-1, -2 & -3 designed with improved kinase selectivity to minimize…”
Get full text

Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer by Dasari, Arvind, Lonardi, Sara, Garcia-Carbonero, Rocio, Elez, Elena, Yoshino, Takayuki, Sobrero, Alberto F., Yao, James C., Garcia-Alfonso, Pilar, Kocsis, Judit, Cubillo, Antonio, Sartore-Bianchi, Andrea, Satoh, Taroh, Randrian, Violaine, Tomasek, Jiri, Chong, Geoff, Yang, Zhao, Pallai, Rajash, Carton, Iris, Tabernero, Josep, Eng, Cathy

“…3604 Background: Effective treatment options are limited for patients (pts) with refractory metastatic colorectal cancer (mCRC). Fruquintinib (F), a highly…”
Get full text

Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report by Gunjur, Ashray, Chong, Geoff, Lim, Adeline, Lau, Eddie, Mitchell, Paul, John, Thomas, Arulananda, Surein

Get full text

Diagnostic medical radiation exposure in surveillance of aggressive lymphoma: clinical trial design should reflect clinical practice by Hawkes, Eliza A, Chong, Geoff, Grigg, Andrew

Get full text

Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study by Sobrero, Alberto F., Dasari, Arvind, Lonardi, Sara, Garcia-Carbonero, Rocio, Elez, Elena, Yoshino, Takayuki, Yao, James C., Garcia-Alfonso, Pilar, Kocsis, Judit, Cubillo, Antonio, Sartore-Bianchi, Andrea, Satoh, Taroh, Randrian, Violaine, Tomasek, Jiri, Chong, Geoff, Yang, Zhao, Schelman, William R., Kania, Marek K., Tabernero, Josep, Eng, Cathy

“…67 Background: The global phase 3 FRESCO-2 study, (NCT04322539) demonstrated that fruquintinib (F) vs placebo (P) significantly improved OS (HR=0.66 [95% CI:…”
Get full text

Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study by Hawkes, Eliza Anne, Lee, Sze Ting, Chong, Geoff, Gilbertson, Michael, Grigg, Andrew, Churilov, Leonid, Fancourt, Tineke, Keane, Colm, Ritchie, David, Koldej, Rachel, Agarwal, Rishu, Manos, Kate, Smith, Charmaine, Houdyk, Kristen, Hawking, Joanne, Barraclough, Allison

“…Abstract only 7560 Background: Standard of care immunochemotherapy in front-line (1L) follicular lymphoma (FL) is highly efficacious but not without…”
Get full text